OTC · INVVY
Healthcare · Drug Manufacturers - Specialty & Generic
$21.85
Up+$0.00 (+0.00%)
Updated Aug 16, 2026, 2:20 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
INVVY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning INVVY.
INVVY research
Company profile and research snapshot.
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 21, 2018 | Jefferies | Hold | — |
No generated briefing is available yet.
fool.com · Dec 7, 2025
New York City-based Newtyn Management increased its stake in Indivior by nearly 1.6 million shares in the third quarter, resulting in a net position change of $62.8 million. The transaction represents a nearly 4.1% change in 13F reportable assets under management.
prnewswire.com · Nov 20, 2025
RICHMOND, Va. , Nov. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INVVY.
No results
No recent SID articles mention INVVY.
